News Releases
- Algernon Pharmaceuticals Announces Green Light From Data and Safety Monitoring Board to Continue its Multinational 2b/3 Human Study of Ifenprodil for Treatment of COVID-19 October 30, 2020
- Algernon Pharmaceuticals Announces 25% Enrollment in its Ifenprodil IPF and Chronic Cough Phase 2 Human Study October 13, 2020
- Algernon Pharmaceuticals Appoints Dr. Mark Swaim MD, PhD to its Medical and Scientific Advisory Board October 9, 2020
- Algernon Announces 75% Enrollment in Multinational Phase 2b/3 Human Study of Ifenprodil for Treatment of COVID-19 October 2, 2020
- Algernon Announces Enrollment of 100 Patients in Multinational 2b/3 Human Study of Ifenprodil for Treatment of COVID-19 September 29, 2020
- Algernon Announces 50% Enrollment in Multinational 2b/3 Human Study of Ifenprodil for Treatment of COVID-19 September 22, 2020
- Algernon Announces Data and Safety Monitoring Board Recommends the Continuation of its Multinational 2b/3 Human Study of Ifenprodil for Treatment of COVID-19 September 16, 2020
- Algernon Announces Enrollment of 50th Patient in Multinational 2b/3 Human Study of Ifenprodil for Treatment of COVID-19 September 2, 2020
- Algernon to Provide Update on its Ifenprodil IPF and Chronic Cough Phase 2 Human Study Featured on BioPub Webcast Hosted by Dr. KSS MD PhD August 25, 2020
- Algernon Updates Market on Analyst Coverage by Mackie Research August 24, 2020